Fraunhofer Institute for Cell Therapy and Immunology IZI

Producing vaccines without the use of chemicals

Research News | January 3, 2019

more info

Successful Evaluation – Future of “Molecular Drug Biochemistry and Therapy Development” Project Group Secured at Fraunhofer IZI from 1 January 2019

Press release | December 13, 2018

more info

Fraunhofer Institute for Cell Therapy and Immunology IZI Strengthens Cooperation with Japanese Research and Industry Partners

Press release | November 19, 2018

more info

New Humanized Mouse Models Expected to Offer Greater Insights into Alzheimer’s Disease

Press Release | November 8, 2018

more info

We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering.

One of the institute's main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology.

Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation.

In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

Business units

Jobs / career

Press

Publications

News

 

Research News / 3.1.2019

Producing vaccines without the use of chemicals

Producing vaccines is a tricky task – especially in the case of inactivated vaccines, in which pathogens must be killed without altering their structure. Until now, this task has generally involved the use of toxic chemicals. Now, however, an innovative new technology developed by Fraunhofer researchers – the first solution of its kind – will use electron beams ...

Press information / 13.12.2018

Successful Evaluation – Future of “Molecular Drug Biochemistry and Therapy Development” Project Group Secured at Fraunhofer IZI from 1 January 2019

Fraunhofer IZI’s “Molecular Drug Biochemistry and Therapy Development” (MWT) project group was set up in October 2013 to explore and develop new molecular strategies for the treatment of neurodegenerative and inflammatory diseases. Over the course of its five-year start-up phase, the group has become a fully-fledged part of the research market and has positioned itself well for the future.

 

 

Press information / 19.11.2018

Fraunhofer Institute for Cell Therapy and Immunology IZI Strengthens Cooperation with Japanese Research and Industry Partners

On October 11, 2018, representatives from Fraunhofer IZI and the Japanese Society for Regenerative Medicine came together in Yokohama, Japan, on the occasion of the BioJapan 2018 conference, where they signed a memorandum of understanding.

Press information / 8.11.2018

New Humanized Mouse Models Expected to Offer Greater Insights into Alzheimer’s Disease

Alzheimer’s disease is a neurodegenerative disorder that would not normally affect mice in their natural habitat. Despite this, the animals are indispensable when it comes to Alzheimer’s research. Novel mouse models are required to more clearly display the complex interactions and relations involved in Alzheimer’s disease; models that would lead to a better understanding of the causes and progression of the disease and – it is hoped – that would facilitate the development of promising therapies and would enable the disease to be diagnosed as early as possible. Researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI have now taken an important step forward in creating more appropriate mouse models. At the beginning of November, the team from Halle (Saale), Germany, attended the Society for Neuroscience’s annual meeting, where they presented for the very first time their latest advances in the development of new animal models, addressing a wide scientific audience.

Contact

Fraunhofer IZI

 

Perlickstraße 1
04103 Leipzig
Germany

Phone +49 341 35536-1000
Fax +49 341 35536-8-1000
E-mail info@izi.fraunhofer.de

 

 

Social Media